ArticleAnnals of the rheumatic diseases2021
Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan.
Article in Annals of the rheumatic diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025).Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- [Analysis of Plasma Metabolic Profile Characteristics in Gouty Arthritis With Dampness Syndrome].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025Article
- Quality Care Assessment in Gout.Current rheumatology reports · 2025Review
- Gout incidence in metformin versus sodium-glucose co-transporter-2 inhibitor users: a retrospective cohort study.Rheumatology (Oxford, England) · 2025Article
- Effect of Dietary Magnesium on the Association Between Serum Uric Acid and Female Infertility.International journal of women's health · 2025Article
- Trends and burden of gout among adolescents aged 10-24 years: insights from the global burden of disease study 2021.Frontiers in public health · 2025Article
- Clustering of gout-related comorbidities and their relationship with gout flares: a data-driven cluster analysis of eight comorbidities.Journal of endocrinological investigation · 2024Article
- The non-causative role of abnormal serum uric acid in intervertebral disc degeneration: A Mendelian randomization study.JOR spine · 2024Article
- Hyperuricemia and associated factors: The case of outpatients at the Bafoussam Regional Hospital- Cameroon, an analytical cross-sectional study.Health science reports · 2024Article
- Exploring the Multifaceted Nexus of Uric Acid and Health: A Review of Recent Studies on Diverse Diseases.Biomolecules · 2023Review
- Update in uric acid, hypertension, and cardiovascular diseases.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Review
- Detailed analysis of the association between urate deposition and bone erosion in gout: a dual-energy computed tomography study.Frontiers in endocrinology · 2023Article
- Correction:Annals of the rheumatic diseases · 2022Article
- The reality of treatment for hyperuricemia and gout in Japan: A historical cohort study using health insurance claims data.Journal of clinical hypertension (Greenwich, Conn.) · 2022Article
- Temporal trends in the prevalence and characteristics of hypouricaemia: a descriptive study of medical check-up and administrative claims data.Clinical rheumatology · 2022Article
- Association of Total Calcium With Serum Uric Acid Levels Among United States Adolescents Aged 12-19 Years: A Cross-Sectional Study.Frontiers in medicine · 2022Article
- Gut Microbiota Characterization in Patients with Asymptomatic Hyperuricemia: probiotics increased.Bioengineered · 2021Article
- Tongbixiao Pills Improve Gout by Reducing Uric Acid Levels and Inhibiting Inflammation.Dose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIn patients with gout, treating to target serum uric acid levels (sUA) of ≤6.0 mg/dL is universally recommended to prevent gout flare. However, there is no consensus on asymptomatic hyperuricaemia. Using Japanese health insurance claims data, we explored potential benefits of sUA control for preventing gout flare in subjects with asymptomatic hyperuricaemia.
methodsThis retrospective cohort study analysed the JMDC Claims Database from April 2012 through June 2019. Subjects with sUA ≥8.0 mg/dL were identified, and disease status (prescriptions for urate-lowering therapy (ULT), occurrence of gout flare, sUA) was investigated for 1 year. Time to first onset and incidence rate of gout flare were determined by disease status subgroups for 2 years or more. The relationship between gout flare and sUA control was assessed using multivariable analysis.
resultsThe analysis population was 19 261 subjects who met eligibility criteria. We found fewer occurrences of gout flare, for both gout and asymptomatic hyperuricaemia, in patients who achieved sUA ≤6.0 mg/dL with ULT than in patients whose sUA remained >6.0 mg/dL or who were not receiving ULT. In particular, analysis by a Cox proportional-hazard model for time to first gout flare indicated that the HR was lowest, at 0.45 (95% CI 0.27 to 0.76), in subjects with asymptomatic hyperuricaemia on ULT (5.0<sUA ≤ 6.0 mg/dL), compared with untreated subjects (sUA ≥8.0 mg/dL).
conclusionsOccurrences of gout flare were reduced by controlling sUA at ≤6.0 mg/dL in subjects with asymptomatic hyperuricaemia as well as in those with gout. TRIAL REGISTRATION NUMBER: UMIN000039985.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.